Ameritas Investment Partners’s VistaGen Therapeutics VTGN Stock Holding History

Ameritas Investment Partners’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-500	Closed	-$1.87K	–	3222
2023 Q1	$1.87K	Hold	500	–	–	﹤0.01%	2959
2022 Q4	$2.69K	Hold	500	–	–	﹤0.01%	2992
2022 Q3	$2K	Hold	500	–	–	﹤0.01%	3012
2022 Q2	$13K	Hold	500	–	–	﹤0.01%	2765
2022 Q1	$19K	Hold	500	–	–	﹤0.01%	2591
2021 Q4	$29K	Hold	500	–	–	﹤0.01%	2471
2021 Q3	$41K	Hold	500	–	–	﹤0.01%	2296
2021 Q2	$47K	Buy	+500	New	+$37K	﹤0.01%	2230

Other funds holding VTGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameritas Investment Partners's VTGN Position: Q2 2023 in Review

Ameritas Investment Partners sold out of VistaGen Therapeutics (VTGN) in Q2 2023, closing a stake of 500 shares — an estimated $1.87K sold.

Ameritas Investment Partners first reported a position in VTGN in Q2 2021 and held it in 8 quarters. The position peaked at $47K in Q2 2021. 33 funds tracked by Wall St. Rank hold VTGN as of Q2 2023.

Ameritas Investment Partners reported no remaining VistaGen Therapeutics position as of Q2 2023 after selling out during the quarter.
Ameritas Investment Partners sold 500 VistaGen Therapeutics shares in Q2 2023, an estimated $1.87K.
Ameritas Investment Partners first reported a position in VistaGen Therapeutics in Q2 2021 and held it in 8 quarters.
Ameritas Investment Partners's VistaGen Therapeutics position peaked at $47K in Q2 2021.
33 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2023.

Based on Ameritas Investment Partners's 13F filing for Q2 2023, filed 11 Aug 2023.